Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.
Guidetti A, Carlo-Stella C, Ruella M, Miceli R, Devizzi L, Locatelli SL, Giacomini A, Testi A, Buttiglieri S, Risso A, Mariani L, Di Nicola M, Passera R, Tarella C, Gianni AM.
Guidetti A, et al.
Cancer. 2011 Nov 15;117(22):5074-84. doi: 10.1002/cncr.26182. Epub 2011 May 12.
Cancer. 2011.
PMID: 21567384
Free article.
Clinical Trial.